← Back to Search

intraoperative imaging camera system for Ovarian Cancer

Phase 1
Waitlist Available
Led By Sunil Singhal
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female patients > 18 years of age
Have a primary diagnosis, or at high clinical suspicion, of primary ovarian cancer (of epithelial type), planned for primary surgical cytoreduction, interval debulking, or have recurrent ovarian cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks post surgery (completion of post-operative follow-up visit)
Awards & highlights

Study Summary

This study is evaluating whether a new imaging system can detect ovarian cancer.

Eligible Conditions
  • Ovarian Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks post surgery (completion of post-operative follow-up visit)
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks post surgery (completion of post-operative follow-up visit) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Compare the performance of different camera imaging systems in assessing the positive predictive values

Trial Design

1Treatment groups
Experimental Treatment
Group I: OTL 38Experimental Treatment2 Interventions
The study drug in question is an Investigational New Drug (IND), folate analog ligand conjugated with an indole cyanine green-like dye called OTL38. There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, completed at least 1 hour prior to intraoperative imaging
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OTL38
2018
Completed Phase 3
~470

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,135 Total Patients Enrolled
8 Trials studying Ovarian Cancer
961 Patients Enrolled for Ovarian Cancer
Abramson Cancer Center at Penn MedicineLead Sponsor
383 Previous Clinical Trials
144,891 Total Patients Enrolled
8 Trials studying Ovarian Cancer
961 Patients Enrolled for Ovarian Cancer
Sunil SinghalPrincipal InvestigatorUniversity of Pennsylvania
2 Previous Clinical Trials
301 Total Patients Enrolled
1 Trials studying Ovarian Cancer
10 Patients Enrolled for Ovarian Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Mar 2025